Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 24

Results For "biopharma"

648 News Found

Novartis to acquire MorphoSys AG for Euro 2.7 billion to strengthen oncology pipeline
News | February 09, 2024

Novartis to acquire MorphoSys AG for Euro 2.7 billion to strengthen oncology pipeline

Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement


Jiangsu Alphamab, 3D Medicines and Glenmark sign license agreement for Envafolimab
News | January 29, 2024

Jiangsu Alphamab, 3D Medicines and Glenmark sign license agreement for Envafolimab

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America


Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr
News | January 26, 2024

Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr

For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)


BenevolentAI appoints former Bayer R&D head Dr. Joerg Moeller as CEO
People | January 25, 2024

BenevolentAI appoints former Bayer R&D head Dr. Joerg Moeller as CEO

An accomplished R&D leader and champion of the application of AI to drug discovery


ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO
People | January 24, 2024

ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO

He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom


Agilent announces new ProteoAnalyzer system
News | January 17, 2024

Agilent announces new ProteoAnalyzer system

Automated parallel capillary electrophoresis system simplifies protein analysis


Shanghai Argo announces multi-program RNAi licenses with Novartis
News | January 11, 2024

Shanghai Argo announces multi-program RNAi licenses with Novartis

Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.


GSK to acquire Aiolos Bio for US$ 1 billion upfront payment
News | January 10, 2024

GSK to acquire Aiolos Bio for US$ 1 billion upfront payment

Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway


Cipla EU to form JV in USA
News | January 07, 2024

Cipla EU to form JV in USA


Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData
News | January 02, 2024

Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData

The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year